Severe asthma: inflammation
More details
Hide details
1st Pneumonology Department, “Sotiria” Hospital, Athens Medical School, National and Kapodistrian University of Athens
Department of Cardiothoracic and Vascular Sciences, University of Padova, Padova, Italy
Corresponding author
Nikoletta Rovina   

1st Department of Pneumonology, University of Athens, Medical School, “Sotiria” Hospital for Diseases of the Chest, 152, Mesogion Ave, Athens GR-11527, Greece
Pneumon 2011;24(3):306-313
Severe asthma is a heterogeneous disease. Identification of specific sub-phenotypes of asthma may further improve our understanding of its pathophysiology. The genetic and environmental elements that may be important in the development of the disease are poorly understood, but it appears that the pathophysiological background of severe asthma includes both allergic and non-allergic elements. Inflammatory cells are usually present and activated in the airways of patients with severe asthma, and persist despite treatment, but their relevance to lack of asthma control and disease severity is largely unknown. Histopathological studies of severe asthma suggest that 1/2 to 2/3 of patients with severe asthma have persistent large airway tissue eosinophils, despite continued administration of high-dose systemic and inhaled steroids. Severe asthma has also been associated with neutrophilic inflammation, but the precise role of neutrophils is not yet clear. Up to 50% of patients with severe asthma, however, show no evidence of increased airway inflammation. “Steroid resistance” may occur at several levels, not all of which are related to lack of effect of steroids on inflammation. It appears that the factors leading to the development of severe asthma are complex and the disease is probably a mixture of various syndromes that have different elements, but also share similarities at the pathophysiological level. A better understanding of the immunological and histopathological phenotypes of severe asthma should enhance our ability both to understand the pathogenesis of these syndromes and to improve our therapeutic approach, leading to better targeting of both current and novel forms of treatment.
Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984;39:131–136.
Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194–1200.
Peat JK, Woolcock AJ, Cullen K. Rate of decline of lung function in subjects with asthma. Eur J Respir Dis 1987;70:171–179.
Ulrik CS, Backer V, Dirksen A. A 10-year follow-up of 180 adults with bronchial asthma: factors important for the decline in lung function. Thorax 1992;47:14–18.
Moraitaki P, Papamichail D, Georgatou N. Severe Asthma: Definitions, risk factors and phenotype characterization. Pneumon 2010;23:260-292.
Rovina N, Gratziou C. Smoking and asthma. Pneumon 2006;19:202-215.
Barnes PJ, Woolcock AJ. Difficult asthma. Eur Respir J 1998;12:1209–1218.
Homer RJ, Elias JA. Consequences of long-term inflammation. Airway remodeling. Clin Chest Med 2000;21:331–343.
Levy BD, Bonnans C, Silverman ES, et al. Diminished lipoxin biosynthesis in severe asthma. Am J Respir Crit Care Med 2005; 172: 824–830.
Vachier I, Bonnans C, Chavis C, et al. Severe asthma is associated with a loss of lx4, an endogenous antiinflammatory compound. J Allergy Clin Immunol 2005; 115: 55–60.
Planaguma A, Kazani S, Marigowda G, et al. Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. Am J Respir Crit Care Med 2008; 178: 574–582.
Comhair SA, Ricci KS, Arroliga M, et al. Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma. Am J Respir Crit Care Med 2005;172: 306–213.
Huynh ML, Malcolm KC, Kotaru C, et al. Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and 15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages. Am J Respir Crit Care Med 2005;172: 972–979.
Vignola AM, Chiappara G, Siena L, et al. Proliferation and activation of bronchial epithelial cells in corticosteroiddependent asthma. J Allergy Clin Immunol 2001; 108: 738–746.
Joos GF, Germonpre PR, Pauwels RA. Role of tachykinins in asthma. Allergy 2000; 55: 321–337.
Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999;160: 1001–1008.
Saetta M, Turato G. Airway pathology in asthma. Eur Respir J 2001; 18: Suppl. 34: 18s–23s.
Carroll NG, Elliot J, Morton AR, James AL. The structure of large and small airways in nonfatal and fatal asthma. Am Rev Respir Dis 1993;147:405–410.
Carroll NG, Mutavdzic S, James AL. Distribution and degranulation of airway mast cells in normal and asthmatic subjects. Eur Respir J 2002;19:879–885.
Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996;154:1505–1510.
Balzar S, Wenzel SE, Chu HW. Transbronchial biopsy as a tool to evaluate small airways in asthma. Eur Respir J 2002;20:254–259.
Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. AmJ Respir Crit Care Med 2005;171:431–439.
Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996; 154: 224–230.
Payne DN, Adcock IM, Wilson NM, Oates T, Scallan M, Bush A. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in children with difficult asthma, after treatment with oral prednisolone. Am J Respir Crit Care Med 2001;164:1376–1381.
ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. Factors associated with persistent airflow limitation in severe asthma. Am J Respir Crit Care Med 2001;164:744–748.
Lemiere C, Ernst P, Olivenstein R, et al. Airway inflammation assessed by invasive and noninvasive means in severe asthma: eosinophilic and noneosinophilic phenotypes. J Allergy Clin Immunol 2006; 118: 1033–1039.
Shannon J, Ernst P, Yamauchi Y, et al. Differences in airway cytokine profile in severe asthma compared to moderate asthma. Chest 2008; 133: 420–426.
Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 1997;99:657–665.
Wenzel SE, Balzar S, Chu HW, Cundall M. The phenotype of steroid dependent severe asthma is not associated with incresaed lung levels of TH-2 cytokines. Presented at the Collegium Internationale Allergolicum, Bornholm, Denmark, 2004.
Simpson JL, Scott RJ, Boyle MJ, et al. Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. Am J Respir Crit Care Med 2005; 172: 559–565.
Chu HW, Trudeau JB, Balzar S, Wenzel S. Peripheral blood and airway tissue expression of transforming growth factor beta by neutrophils in asthmatic subjects and normal control subjects. J Allergy Clin Immunol 2000;106:1115–1123.
Miranda C, Busacker A, Balzar S, Trudeau J, Wenzel SE. Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. J Allergy Clin Immunol 2004;113:101–108.
Wenzel SE. Severe asthma in adults. Am J Respir Crit Care Med 2005;172:149–160.
Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ. Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 1997;156:737–743.
Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir CritCare Med 1999;160:1532–1539.
Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. J Immunol 1995; 154: 4719–4725.
Gaga M. Fixed obstruction in severe asthma: not just a matter of time. Eur Respir J 2004; 24: 8–10.
Gibson PG, Simpson JL, Saltos N. Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 2001; 119: 1329–1336.
Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005; 60:1012–1018.
Puddicombe SM, Polosa R, Richter A, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14: 1362–1374.
Hamilton LM, Torres-Lozano C, Puddicombe SM, et al. The role of the epidermal growth factor receptor in sustaining neutrophil inflammation in severe asthma. Clin Exp Allergy 2003; 33: 233–240.
Wenzel SE, Balzar S, Cundall M, Chu HW. Subepithelial basement membrane immunoreactivity for matrix metalloproteinase 9: Association with asthma severity, neutrophilic inflammation, and wound repair. J Allergy Clin Immunol 2003;111:1345–1352.
Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M. Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 2003;167:1360–1368.
Gagliardo R, Chanez P, Mathieu M, et al. Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am J Respir Crit Care Med 2003;168:1190–1198.
Sher E, Leung DYM, Surs W, et al. Steroid-resistant asthma: cellular mechanisms contributing to inadequate response to glucocorticoid therapy. J Clin Invest 1994;93:33–39.
Haldar P, Pavord ID. Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 2007;119:1043–52.
Kam JC, Szefler SJ, Surs W, Sher ER, Leung DY. Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids. J Immunol 1993;151:3460–3466.
Leung DY, Hamid Q, Vottero A, et al. Association of glucocorticoid insensitivity with increased expression of glucocorticoid receptor beta. J Exp Med 1997;186:1567–1574.
Ito K, Caramori G, Lim S, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002;166:392–396.
Cosio BG, Mann B, Ito K, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med 2004;170:141–147.
Balzar S, Chu HW, Silkoff P, et al. Increased TGF-beta2 in severe asthma with eosinophilia. J Allergy Clin Immunol 2005;115:110– 117.
Minshall EM, Leung DYM, Martin RJ, et al. Eosinophil-associated TGF-_1 mRNA expression and airway fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997;17:326–333.
Wenzel S, Barnes S, Westcott J, et al. TGF-beta IL-13 increases eotaxin in a cell and mediator specific manner associated with increases in procollagen [abstract]. Am J Respir Crit Care Med 2002;165:A730.
Davies D, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: New insights. J Allergy Clin Immunol 2003;111:215-25.
James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989;139:242–246.
Holgate ST, Holloway J, Wilson S, et al. Epithelial mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac Soc 2004; 1: 93–98.
Sobonya RE. Quantitative structural alterations in longstanding allergic asthma. Am Rev Respir Dis 1984; 130:289–292.
Mauad T, Silva LF, Santos MA, et al. Abnormal alveolar attachments with decreased elastic fiber content in distal lung in fatal asthma. AmJ Respir Crit Care Med 2004;170:857–862.
Bousquet J, Lacoste J-Y, Chanez P, Vic P, Godard P, FrancoisBernard M. Bronchial elastic fibers in normal subjects and asthmatic patients. Am J Respir Crit Care Med 1996;153:1648–1654.
Mauad T, Xavier ACG, Saldiva PHN, Dolhnikoff M. Elastosis and fragmentation of fibers of the elastic system in fatal asthma. Am JRespir Crit Care Med 1999;160:968–975.
Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158:1945–1950.
Lemjabbar H, Gosset P, Lamblin C, et al. Contribution of 92 kDa gelatinase/Type IV collagenase in bronchial inflammation during status asthmaticus. Am J Respir Crit Care Med 1999;159:1298–1307.
Journals System - logo
Scroll to top